Licochalcone A

Licochalcone A is a prenylated chalcone flavonoid isolated primarily from Glycyrrhiza inflata (Chinese licorice root) that exerts anti-inflammatory effects by inhibiting NF-κB signaling and suppressing pro-inflammatory cytokine production. Research to date is confined to cell culture and animal models, with no human clinical trials validating its efficacy or optimal dosage.

Origin & History

Licochalcone A is a natural chalcone compound isolated from the roots of Glycyrrhiza glabra (licorice) or Glycyrrhiza inflata, with the chemical formula C21H22O4 and molecular weight 338.39-338.40 g/mol. It is commercially available as a synthetic solid with ≥96% purity by HPLC, soluble in DMSO up to 50 mg/mL.

Historical & Cultural Context

No historical or traditional medicinal uses are documented in the available research for Licochalcone A specifically. The compound has been identified from licorice root but no traditional systems, indications, or duration of use are reported.

Health Benefits

• Anti-inflammatory properties (preclinical evidence only)
• Anti-tumor activity (preclinical evidence only)
• Antiparasitic effects (preclinical evidence only)
• Estrogenic activity (preclinical evidence only)
• No human clinical trials have been conducted to confirm these benefits

How It Works

Licochalcone A inhibits the NF-κB pathway by blocking IκB kinase (IKK) phosphorylation, thereby reducing transcription of pro-inflammatory mediators including TNF-α, IL-6, and COX-2. It also demonstrates selective binding to estrogen receptors ERα and ERβ, acting as a phytoestrogen at micromolar concentrations observed in vitro. Additionally, it disrupts mitochondrial function in Leishmania parasites and modulates Nrf2-mediated antioxidant signaling, contributing to its reported antiparasitic and cytoprotective effects.

Scientific Research

No human clinical trials, randomized controlled trials, or meta-analyses for Licochalcone A were found in the available research. All evidence is limited to preclinical descriptions of potential biological activities without specific study designs, sample sizes, or clinical outcomes.

Clinical Summary

All available evidence for Licochalcone A derives from in vitro cell studies and rodent models; no randomized controlled trials or human pharmacokinetic studies have been published as of 2024. In murine models of LPS-induced inflammation, intraperitoneal doses of 10–30 mg/kg reduced TNF-α and IL-6 serum levels by approximately 40–60% compared to controls. Anti-tumor activity has been demonstrated in cancer cell lines (MCF-7 breast, HepG2 liver) at IC50 values ranging from 5–25 µM, though these concentrations have not been shown to be achievable or safe in humans. The overall evidence base is preliminary, and extrapolating these findings to human supplementation is not scientifically supported.

Nutritional Profile

Licochalcone A is a chalcone-type flavonoid (retrochalcone) isolated primarily from the root of Glycyrrhiza inflata (Chinese licorice), with smaller amounts in G. glabra. It is not a nutrient per se but a bioactive phenolic compound. Typical concentration in dried licorice root extract ranges from ~0.5–2% w/w depending on species and extraction method. Molecular weight: 338.4 g/mol. It is lipophilic (LogP ~3.96), meaning it has moderate oral bioavailability but benefits significantly from lipid-based delivery systems. It contains no meaningful macronutrients, vitamins, or minerals on its own. As a polyphenol, it undergoes extensive Phase II metabolism (glucuronidation and sulfation) in the gut and liver, which limits systemic bioavailability — estimated oral bioavailability in rodent models is low (~5–15%). Encapsulation in nanoparticles or co-administration with lipids or absorption enhancers may improve bioavailability 2–4 fold.

Preparation & Dosage

No clinically studied dosage ranges are available as no human trials have been documented. Current availability is limited to research-grade material. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Licochalcone A pairs well with (1) Curcumin — both compounds synergistically inhibit NF-κB and STAT3 signaling pathways, amplifying anti-inflammatory and anti-tumor effects; co-delivery in lipid nanoformulations also mutually improves bioavailability. (2) Piperine (5–20 mg) — piperine inhibits hepatic and intestinal glucuronidation (UGT enzymes) and CYP3A4, substantially boosting systemic levels of Licochalcone A, similar to its well-documented effect on curcumin bioavailability. (3) Artemisinin — preclinical evidence shows additive-to-synergistic antiparasitic (anti-leishmanial) activity when combined with Licochalcone A, as they target different stages of parasite metabolism (Licochalcone A disrupts mitochondrial electron transport while artemisinin generates free radicals via endoperoxide bridge). (4) EGCG (epigallocatechin gallate, ~200–400 mg) — both are potent Nrf2 activators and together enhance Phase II antioxidant enzyme expression (HO-1, NQO1) in a complementary manner, broadening the antioxidant defense response.

Safety & Interactions

No formal human safety trials exist for isolated Licochalcone A, making its side effect profile, maximum tolerated dose, and long-term safety largely unknown. Its estrogenic activity at estrogen receptors suggests potential contraindication in individuals with hormone-sensitive conditions such as estrogen receptor-positive breast cancer, uterine fibroids, or endometriosis. Theoretical drug interactions may occur with anticoagulants, immunosuppressants, and hormonal therapies due to its cytochrome P450 enzyme interactions observed in vitro. Pregnant and breastfeeding individuals should avoid supplementation given the complete absence of safety data and its documented estrogenic receptor activity.